Actinium Pharmaceuticals, Inc. (ATNM) Operating income 2016–2025
Actinium Pharmaceuticals, Inc. (ATNM) annual operating income history from SEC filings — each fiscal year as reported.
-$36.2MFY2025 · since FY2016: -$26.8M → -$36.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$36.2M | +13.9% |
| FY2024 | -$42.1M | +18.9% |
| FY2023 | -$51.9M | -52.2% |
| FY2022 | -$34.1M | -36.6% |
| FY2021 | -$25.0M | -11.5% |
| FY2020 | -$22.4M | -1.5% |
| FY2019 | -$22.1M | +7.4% |
| FY2018 | -$23.8M | +11.5% |
| FY2017 | -$26.9M | -0.2% |
| FY2016 | -$26.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ATNM financial trends
ATNM RevenueATNM Net incomeATNM Net marginATNM Gross profitATNM Gross marginATNM Operating marginATNM Operating cash flowATNM Free cash flowATNM Capital expendituresATNM Return on equityATNM Stock buybacksATNM Dividends paidATNM Total assetsATNM Total liabilitiesATNM Shareholders’ equityATNM overview →